肝移植受者乙型肝炎的管理。
The Management of Hepatitis B in Liver Transplant Recipients.
机构信息
Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA; Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
出版信息
Clin Liver Dis. 2016 Nov;20(4):721-736. doi: 10.1016/j.cld.2016.06.004. Epub 2016 Aug 9.
Liver transplant (LT) is now an established indication for patients with chronic hepatitis B, mainly because of the development and use of hepatitis B immunoglobulin (HBIG) and oral antivirals for prophylaxis. The combination of low-dose HBIG and antivirals has been considered the standard prophylaxis regimen to prevent post-LT recurrence of hepatitis B. The important remaining issues are related to the long-term cost of HBIG and the risk of escape hepatitis B virus (HBV) mutants. Strategies for prevention of HBV after LT are constantly improving. With the availability of new nucleoside/nucleotide analogues, new post-LT strategies also should emerge.
肝移植（LT）现在是慢性乙型肝炎患者的明确适应证，主要是因为乙型肝炎免疫球蛋白（HBIG）和口服抗病毒药物的发展和应用，用于预防。低剂量 HBIG 和抗病毒药物的联合应用被认为是预防 LT 后乙型肝炎复发的标准预防方案。重要的遗留问题与 HBIG 的长期成本和乙型肝炎病毒（HBV）突变体逃逸的风险有关。LT 后预防乙型肝炎的策略在不断改进。随着新的核苷/核苷酸类似物的出现，新的 LT 后策略也应该出现。
Zotero 插件